Medications for opioid use disorder remain underutilized in U.S. carceral settings, largely due to staffing burdens tied to daily dosing. This study used a cost impact model to evaluate staff time and cost differences across MOUD types, including methadone, oral buprenorphine, extended-release buprenorphine, and naltrexone. Findings suggest that using long-acting injectable MOUD, such as BUP-XR, may significantly reduce staffing time and costs, improving treatment feasibility in correctional environments.